Type of Cancer
Lung
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.